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Background: The deregulation of microRNAs has been reported to play a pivotal role in hepatocellular carcinoma
(HCC). MiR-126-3p has been reported to be associated with poor prognosis in HCC. However the underlying
mechanism of miR-126-3p in HCC remains unclear.
Methods: The expression levels of miR-126-3p in HCC tissues and cells were detected by RT-PCR. Transwell
assay and capillary tube formation assay were applied to assess the metastasis and angiogenesis in vitro. Nude
mice subcutaneous tumor model was used to perform in vivo study. Dual- luciferase reporter assay was conducted
to confirm the direct binding of miR-126-3p and target genes. The changes of biomarker protein levels were examined
by western blot and Immunohistochemistry.
Results: We observed that the miR-126-3p expression levels in HCC tissues and cells were significantly down-regulated.
Through gain- and loss- of function studies, we showed that miR-126-3p dramatically inhibited HCC cells from
migrating and invading extracellular matrix gel and suppressed capillary tube formation of endothelial cells
in vitro. Furthermore, overexpression of miR-126-3p significantly reduced the volume of tumor and microvessel
density in vivo. LRP6 and PIK3R2 were identified as targets of miR-126-3p. Silencing LRP6 and PIK3R2 had similar effects
of miR-126-3p restoration on metastasis and angiogenesis individually in HCC cells. Furthermore, the miR-126-3p level
was inversely correlated with LRP6 and PIK3R2 in HCC tissues. In addition, the rescue experiments indicated that the
metastasis and angiogenesis functions of miR-126-3p were mediated by LRP6 and PIK3R2.
Conclusion: Our results demonstrates that deregulation of miR-126-3p contributes to metastasis and angiogenesis in
HCC. The restoration of miR-126-3p expression may be a promising strategy for HCC therapy.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon human cancers in the world, particularly in China
[1]. Active angiogenesis and frequent metastasis are two
major characteristics of HCC, which obviously lead to
poor prognosis [2]. MicroRNAs (miRNAs) are a class of
highly conserved short RNAs that regulate diverse cel-
lular processes by binding to the 3′untranslated region
(3′UTR) of target messenger RNAs (mRNAs) [3,4]. In-
creasing numbers of studies have suggested that miRNAs* Correspondence: drwujian@hotmail.com; shusenzheng@zju.edu.cn
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unless otherwise stated.play an important role in HCC development, such as
apoptosis [5,6], proliferation [7,8], autophagy [9], EMT.
[10]. To date, relatively few studies have reported that
miRNAs possess both metastasis and angiogenesis func-
tions in HCC, such as mir-29b [11], mir-195 [12]. There-
fore, miRNAs targeting mRNAs relevant in metastasis and
angiogenesis in HCC might be a promising strategy for
HCC therapy.
MiR-126-3p has been reported to act as a tumor sup-
pressor by targeting CRK, SOX2, IRS-1 in several cancer
types [13-15]. Further studies on zebrafish highlight its sig-
nificant role in angiogenesis [16,17]. And miR-126-3p has
been shown to inhibit angiogenesis in cancer developmentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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esis remains unclear. A previous study indicated that
miR-126-3p associates with the recurrence rate after
liver transplantation and suppresses metastasis in HCC
[19]. But the detailed mechanism mediating metastasis
remains unknown. In this study, we examined the ex-
pression patterns of miR-126-3p in HCC comparing to
normal tissue. Both gain and loss of function indicated
miR-126-3p suppressed metastasis and angiogenesis in
HCC cells. Moreover in vivo study verified the anti-
angiogenesis function of miR-126-3p. We then illustrated
that LRP6 and PIK3R2 were direct targets of miR-126-3p
in mediating anti-metastasis and anti-angiogenesis. Our
findings demonstrate the importance of deregulation of
miR-126-3p in promoting HCC progression and indicate
that miR-126-3p might serves as a therapeutic target for
HCC.
Materials and methods
Patients and tissue specimens
HCC tissues and their corresponding normal liver
tissues were obtained from 70 HCC patients undergoing
resection of HCC from 2009 to 2010 in our hospital
(First Affiliated Hospital, Zhejiang University School of
Medicine, Zhejiang, China). This study was approved by
the Ethics Committee of Zhejiang University and informed
consent was obtained from each patient.
Cell lines and culture
Normal liver cell line L02 and liver cancer cell lines
HepG2, SMMC-7721, BEL-7402 were purchased from
the American Type Culture Collection (Manassas, VA,
USA) and the Shanghai Institute of Cell Biology (Shanghai,
China). All cell lines were maintained in the recommended
culture conditions and incubated at 37°C in a humidified
environment containing 5%CO2.
RNA Oligoribonucleotides construction and lentiviral
transduction
MiR-126-3p mimics were purchased from GenePharma
(Shanghai, PR China). Anti-miR-126-3p inhibitor was pur-
chased from Invitrogen. Si-LRP-6, si-pik3r2 and its all-star
negative control were purchased from Qiagen and their
sequences were listed in Additional file 1: Table S1. For
lentiviral vector construction, the oligonucleotide of ma-
ture miR-126-3p (5′-ucguaccgugaguaauaaugcg-3′) was
chemosynthesized, amplified and cloned into GV209-Puro
Vectors by Genechem Co., Ltd (Shanghai, China). The
correct sequences and insertions were confirmed by DNA
sequencing. For lentiviral infection, cells were plated at a
concentration of 3 × 104 cells in 24-well plates overnight
and were then infected at MOI of 30 in the presence of
polybrene (5 μg/ml) for 8 hours. Infected cells were
then cultured for 72 hours with 10% FBS medium. Thenpuromycin-resistant cell clones were picked and passaged
in medium containing puromycin at a concentration of
5 μg/mL. Lentivirus-mediated overexpression of miR-
126-3p was verified by qRT-PCR.
RT-PCR, western blot and Immunohistochemistry (IHC)
The detailed procedure of RNA isolation, RT-PCR, western-
blot and immunohistochemistry were performed as de-
scribed before [20]. GAPDH, RNU6B and β-actin were
used as internal control. The primer sequences were
listed in Additional file 1: Table S2. The primary anti-
bodies used for western blot and IHC: LRP6 (abcam,
ab75358, 1:1000, ab24386, 1:300), beta-catenin (epitomics,
1247–1, 1:1000), PIK3R2 (abcam, ab28356, 1:1000),
phospho-ser473-AKT (epitomics, 2118–1, 1:1000), CD34
(epitomics, 2749–1, 1:500), β-actin (A5441, Sigma-Aldrich,
1:2000).
Staining score of CD34, which represented the microves-
sel density (MVD), was evaluated by counting microvessels
(any discrete cluster or single cell). We first scanned the
stained microvessels in the 100 ×magnification and we
chose three most intensely vascularized areasm. Then we
counted the microvessels at the magnification of 200× and
the mean microvessels number of these three areas were
recorded.
Staining score of LRP6 and PIK3R2 was evaluated
using a modified Histo-score (H-score), which consisted
of a semi-quantitative assessment of both fraction of
positive cells (0%-100%) and intensity of staining (no 0,
weak 1, moderate 2, or strong 3). The intensity and
fraction scores were then multiplied to obtain H-score,
which ranged from 0 to 3.
Isolation and Culture of Human Umbilical Vein
Endothelial Cells (HUVECs)
The vein of each umbilical cord was rinsed with 1 × PBS
three times, and then perfused and incubated with 0.25%
trypsin/0.04% EDTA (Gibico) for 15 min at 37°C with
the ends of the vein clamped. Then the trypsin/EDTA
solution was centrifuged at 500 g for 5 min and the
HUVECs were re-suspended in Serum Free Medium for
Endothelial Cells (SFM, Invitrogen), supplemented with
20% FBS, 0.1 mg/ml of heparin and supplements. All
HUVECs used in this study were at passages 3–6.
Preparation of Tumor Cell-Conditioned Medium (TCM)
The cells were plated and transfected in six-well plates.
After 48 h, the supernatant medium was removed and
replaced by 1.5 ml SFM per well. Following 24 hrs of
incubation, the TCM was collected and centrifuged at
5000 g for 10 min to discard cells and cell debris. Then
each TCM was adjusted to the number of living cells of
corresponding well. The TCM was stored at 80°C until
used.
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HUVECs (2 × 104/well) were added to matrigel-coated
96-well plates and incubated at 37°C for 6–8 h with 75%
TCM. HUVECs were photographed under an inverted
microscope. The branch points of the formed tubes, which
represent the degree of angiogenesis in vitro, were
scanned and quantitated at 100× magnification.
In vitro assays of migration and invasion
For the migration and invasion assay, 5 × 104 HCC cells
were re-suspended in a serum-free medium and placed
on the upper chamber of transwell chambers (24-well
insert; pore size: 8 μm; BD Biosciences) while culture
medium containing 10% FBS was added in the lower
chamber. For invasion assay, the membrane was coated
with matrigel to form a matrix barrier. The incubation
time was 24 hrs for migration and 48 hrs for invasion.
The cells on the lower surface of the membrane were
fixed in 70% ethanol and stained with crystal violet. Each
blue point indicated an individual cell and all the images
were scanned and counted at 200× magnification.
Luciferase reporter assay
Hep-G2 and BEL-7402 cells were seeded in a 24-well plate
until 50-70% confluence and then were co-transfected
with miR-126-3p or NC and 100 ng of firefly luciferase re-
porter plasmid that contained either the wild-type or mu-
tant 3′UTR of the target gene. 48 hours after transfection,
cells were collected and applied to a dual-luciferase re-
porter assay (promega, E2920). The tests were repeated in
three independent experiments.
Nude mice xenograft assay
All experimental procedures involving animals were
performed in accordance with the Guide for the Care and
Use of Laboratory Animals (NIH publications Nos. 80–23,
revised 1996), and conforming to the institutional ethicalFigure 1 The expression levels of miR-126-3p in HCC tissues and HCC
lower than corresponding non-tumor tissues. (B) Compared to L02, most
Expression levels of miR-126-3p were determined by qRT-PCR and normguide-lines for animal experiments. Hep-G2 cells (1 × 107),
which were stably expressing mir-126 or NC, were sus-
pended in 100 μl PBS and then injected subcutaneously
into the posterior flank of female BALB/c athymic nude
mice. Tumor volumes in mice were measured with a slide
caliper every week until the scarification. Twelve nude
mice were included and they were sacrificed 6 weeks after
injection. Results are presented as mean ± standard error
of the mean.
Statistical analysis
The difference between groups was analyzed using a
Student t test. The association between mir-126 expres-
sion and clinico-pathological variables was assessed by
chi-square tests. Statistical analysis was performed with
SPSS 15.0 and GraphPad Prism 5.0. P < 0.05 was consid-
ered statistically significant.
Results
MiR-126-3p is significantly down-regulated in liver cancer
tissues and liver cancer cells
The expression of miR-126-3p was analyzed by RT-PCR
and normalized to an endogenous control (U6 RNA). In
70 pairs of HCC tissues, the expression of miR-126-3p
was significantly down-regulated in tumors tissues ver-
sus adjacent non-tumor liver tissues (Figure 1A). Among
these 70 cases, 62 cases revealed a relative lower level in
HCC, which suggested that reduction of miR-126-3p
was a frequent event in human HCC. To investigate the
clinical relevance of miR-126-3p in HCC, the median of
all 70 cases was chosen as the cutoff point for separating
low-miR-126-3p (n = 35) from high-miR-126-3p express-
ing tumors (n = 35). Our results showed that miR-126-
3p expression was not significantly associated with any
single clinicopathological features (Table 1). Then we
also measured miR-126-3p expression in a panel of hu-
man HCC cell lines as wells as normal liver cell linecell lines. (A) The level of miR-126-3p in 70 HCC tumors was much
HCC cell lines displayed much lower expressions of miR-126-3p.
alized to an endogenous control (U6 RNA). **P < 0.01.
Table 1 The relationship between miR-126-3p expression
and clinicopathological characteristics in human HCC
patients
Variables All patients miR-126-3p expression P value
(n = 70) Low* High*
Age (years)
≤55 24 12 12 1
>55 46 23 23
Gender
Male 62 31 31 1
Female 8 4 4
Size of tumor (cm)
≤5 30 12 18 0.147
>5 40 23 17
Number of tumor
Single 54 25 29 0.255
Multiple 16 10 6
Portal vein invasion
Negative 46 22 24 0.615
Positive 24 13 11
TNM staging
I, II 37 15 23 0.094
III 33 20 13
Grade
Well + Moderate 61 29 32 0.284
Poor 9 6 3
AFP (ng/ml)
≤400 39 16 23 0.092
>400 31 19 12
*The median expression level was used as the cut-off. Low expression of
miR-126-3p in 35 patients was classified as values below the 50th percentile.
High miR-126-3p expression in 35 patients was classified as values at or above
the 50th percentile.
For analysis of correlation between miR-126-3p expressions and clinical features,
chi-square tests were used. Results were considered statistically significant
at P <0.05.
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cancer cell lines (Figure 1B). The data above suggests
that miR-126-3p decreases in both liver cancer tissues
and cells.MiR-126-3p inhibits tumor metastasis and angiogenesis
in vitro
To explore the potential role of miR-126-3p in HCC metas-
tasis, we transfected HCC cells with miR-126-3p mimics
(Additional file 2: Figure S1C) and performed in vitro trans-
well assays in HepG2 and SMMC-7721 cells, which
displayed lowest expressions of miR-126-3p. Compared
to NC, HCC cells transfected with miR-126-3p mimics
significantly reduced the number of cells invading ormigrating the chamber membrane with or without
matrigel (Figure 2A,B).
We next performed capillary tube formation assay to
elucidate the role of miR-126-3p in HCC angiogenesis.
TCM from HepG2 or SMMC-7721 cells transfected with
miR-126-3p mimics inhibited HUVECs to form capillary-
like structures compared with TCM from cells transfected
with NC (Figure 2C).
Then we carried out loss-of function study by using
miR-126-3p inhibitor, which dramatically decreased the
endogenous level of miR-126-3p to further verify the func-
tion of miR-126-3p in HCC (Additional file 2: Figure S1C).
The HCC cell line we selected was BEL-7402, which
expressed relatively high level of miR-126-3p. As expected,
suppression of miR-126-3p in BEL-7402 promoted the
ability of metastasis and angiogenesis (Additional file 3:
Figure S2A,B). Collectively, both gain- of function (GOF)
and loss- of function (LOF) studies suggest the suppressive
effects of miR-126-3p on HCC cells metastasis and angio-
genesis in vitro.
MiR-126-3p inhibits tumor proliferation and angiogenesis
in vivo
To further validate the role of miR-126-3p in HCC, we
performed in vivo assays by subcutaneously injecting
Hep-G2 cells stably expressing miR-126-3p or control
vector (Additional file 2: Figure S1B). The subcutaneous
tumors were observed and measured regularly, and mice
were sacrificed 6 weeks after HCC cells implantation.
We found that the average tumor volume of Hep-G2
cells stably overexpressing miR-126-3p was significantly
smaller than their control group (Figure 3A).
Next, we excised the subcutaneous tumors and per-
formed IHC to detect the expression level of CD34 of
each group, which indicates the micro-vessels expres-
sion. As shown in Figure 3B, the group of miR-126-3p
overexpression displayed dramatically lower level of CD34,
compared to the group of NC. Then, we further analyzed
the association between miR-126-3p level and angiogenesis
in the same 70 human HCC tissues. Obviously, the MVD
level was inversely correlated with miR-126-3p expression
(Figure 3C). The results above indicate that miR-126-3p
suppresses tumor proliferation and angiogenesis in vivo.
MiR-126-3p inhibits HCC metastasis by directly targeting
LRP6
Next, we searched for a candidate target gene respon-
sible for metastasis suppression of miR-126-3p in HCC
cells. By comprehensive analysis of miRanda, TargetScan,
and PicTar algorithms, LRP6 was chosen as a candidate
target of mir-126 (Figure 4A), which had been reported
to have a suppressive role of metastasis in HCC and re-
ported as a target in 293 T cells [21]. The dual-luciferase
reporter assays in Hep-G2 cells and BEL-7402 cells
Figure 2 (See legend on next page.)
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Figure 2 MiR-126-3p inhibits tumor metastasis and angiogenesis in vitro. (A, B) Representative images of invasion (A) and migration (B) assays
of Hep-G2 cells and SMMC-7721 cells transfected with miR-126-3p mimics or NC. (C) HUVECs were cultured in the presence of 75% TCM from Hep-G2
and SMMC-7721 cells transfected with miR-126-3p mimics or NC. Representative images of tube formation assays and the number of branch points
were shown. NC indicated negative control. *P < 0.05. **P < 0.01.
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significantly inhibited the activity of firefly luciferase
reporter with wild-type 3′UTR of LRP6 but not mu-
tant 3′UTR of LRP6, while the inhibition of miR-126-
3p revealed an opposite result (Figure 4B). Further,
western blot assay indicated that the expression level
of miR-126-3p inversely correlated with LRP6 as well
as its downstream target beta-catenin (Figure 4C). More-
over, IHC of xenografts from the miR-126-3p group
showed dramatically lower expression of LRP6 comparedFigure 3 Mir-126-3p suppresses tumor growth and angiogenesis in v
growth of subcutaneous tumor growth. Growth curve and subcutaneous x
tumors of lenvi-miR-126 or lenvi-NC were immunohistochemically staine
density. (C, D) HCC with lower miR-126-3p expression showed higher M
and was determined from the three most intensely vascularized areas o
and PIK3R2 was performed at a magnification of 400×. The median of al
group (n = 35) from high miR-126-3p group (n = 35) in (C). *P < 0.05. **P < 0.0to the NC group (Figure 4D). In addition, in these 70
HCC cases, miR-126-3p level was inversely correlated
with LRP6 expression (Figure 3D).
Then, we explored the role of LRP6 in HCC metasta-
sis. As is shown in Additional file 4: Figure S3A, si-LRP6
obviously decreased the ability of migration and invasion
of HCC cells. To verify the vital role of LRP6 in mediat-
ing miR-126-3p’s effects on metastasis, BEL-7402 cells
were co-transfected with anti-miR-126-3p and si-LRP6. As
a result, si-LRP6 suppression attenuated the pro-metastasisivo. (A) Overexpression of miR-126-3p significantly suppressed the
enograft tumors removed were shown. (B) Subcutaneous xenograft
d for CD34. Tumors of lenvi-miR-126 displayed lower microvessel
VD, LRP6 and PIK3R2. MVD was evaluated based on CD34 staining
f each section at a magnification of 200×. The evaluation of LRP6
l 70 cases was chosen as the cutoff point for separating low miR-126-3p
1.
Figure 4 LRP6 and PIK3R2 are direct targets of miR-126-3p. (A) MiR-126-3p and its putative binding sequence in the 3′UTR of LRP6 and
PIK3R2. The mutant miR-126-3p binding site was generated in the complementary site for the seed region of miR-126-3p. (B) Hep-G2 and BEL-7402
cells were co-transfected with miR-126-3p mimics or NC and wild-type or its mutant-type (either LRP6 or PIK3R2), and the luciferase activities were
examined. The firefly luciferase activity of each sample was normalized to the Renilla luciferase activity. (C) Western blot results of endogenous
LRP6, PIK3R2, beta-catenin and p-AKT proteins in HCC cells transfected with miR-126-3p mimics or anti-mir-126-3p and its NC. (D) Analysis of LRP6 and
PIK3R2 expression in subcutaneous tumors by immunohistochemistry. NC indicated negative control, **P < 0.01.
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the protein level of LRP6 in each group, which was proved
to conform to the functional outcomes (Figure 5D). These
results provided strong evidence that LRP6 is a target of
miR-126-3p in HCC and mediates the metastasis function
of miR-126-3p in HCC.Figure 5 The effects of LRP6 and PIK3R2 alterations on miR-126-3p fu
showed that the trans-cells of the “rescue” group (anti-126 + si-LRP6) signif
showed that the group co-transfected with PIK3R2 and 126-mimics formed m
performed to assess the protein levels of LRP6 and PIK3R2 in co-transfecMiR-126-3p repressed HCC angiogenesis by negatively
regulating PIK3R2/P-AKT expression
As both in vitro and in vitro assays showed that miR-
126-3p inhibited angiogenesis, we then explored the mo-
lecular mechanism underlying the effects. Among the
predicted targets of miR-126-3p, we chose PIK3R2 asnctions in Hep-G2 cells. (A, B) Both invasion and migration assays
icantly reduced compared with anti-126 group (C) Tube formation assays
ore tube branches than 126-mimics group (D) Western bolt was
tion assays. NC indicated negative control, *P < 0.05. **P < 0.01.
Du et al. Journal of Translational Medicine 2014, 12:259 Page 9 of 11
http://www.translational-medicine.com/content/12/1/259the potential target mediating angiogenesis of mir-126,
which is well known to phosphorylate AKT and then
promoted angiogenesis [22,23]. Like reported in other
researches in 293 T cells [16,17], we demonstrated that
miR-126-3p was shown to directly bind to the 3′UTR of
PIK3R2 by both up-regulation and inhibition of miR-126-
3p in Hep-G2 and BEL-7402 cells (Figure 4B). While we
enhanced the expression level of miR-126-3p in HCC
cells, western blot displayed a decrease protein level of
PIK3R2 and phosphorylation of AKT. Further the inhib-
ition of miR-126-3p enhanced the expression of PIK3R2
and P-AKT (Figure 4C). Besides, 70 HCC tissues and
subcutaneous tumors from mice also indicated an inverse
correlation of miR-126-3p and PIK3R2 (Figures 3C, 4D).
Then we suppressed the level of PIK3R2 in HCC cells to
elucidate its role in HCC angiogenesis. Similar to miR-
126-3p overexpression, silencing of PIK3R2 impaired
the formation of capillary-like structures of HUVECs
(Additional file 4: Figure S3B). We further performed
“rescue” study in Hep-G2 cells, namely, TCM from co-
transfection of miR-126-3p mimics and PIK3R2-ORF
partially attenuated the anti-angiogenesis effects of TCM
from miR-126-3p mimics (Figure 5C). Additionally, the
PIK3R2 level showed a similar result in the “rescue” assay
(Figure 5D). These data suggests that miR-126-3p sup-
presses angiogenesis in HCC through PIK3R2/P-AKT
pathway.
Discussion
It is well known that HCC is a malignant cancer charac-
terized by frequent metastasis and angiogenesis. To date,
mRNAs and microRNAs associated with HCC develop-
ment are innumerably reported, among which mRNAs
and microRNAs pro- or anti- metastasis and angiogen-
esis remain highlights in recent several years, such as
twist1 [24], CXCR6 [25], vasohibin2 [26], mir-29b [6],
mir-195 [12]. And miRNAs possessing anti- metastasis
and angiogenesis functions are thought to be a novel
anti-HCC targets.
In a previous study, miR-126-3p has been reported to
be associated with poor survival after liver transplant-
ation by promoting metastasis in HCC [19]. Here, we,
for the first time, illuminate down-regulation of miR-
126-3p expression in HCC. And both gain- and loss- of
function assays indicated that miR-126-3p plays a vital
role in anti-metastasis and anti-angiogenesis in vitro.
Further in vivo assay, miR-126-3p was inversely corre-
lated with vessel marker CD34. And tumor sizes of miR-
126-3p overexpression group were much smaller, which
might be attributed to less microvessels. Moreover, in
the same 70 HCC tissues, the expressions of miR-126-3p
and CD34 also revealed an inverse correlation.
The fundamental way mediating functions of miRNAs
is to regulate their target genes by direct cleavage of themRNA or by inhibition of protein synthesis [27]. We
then disclosed that miR-126-3p inhibited metastasis and
angiogenesis by targeting LRP6 and PIK3R2, respect-
ively. And the evidence is listed as follows: 1) the protein
levels of LRP6 and PIK3R2 were decreased after overex-
pression of miR-126-3p in vitro or in vivo. 2) Overex-
pression of miR-126-3p decreased the luciferase reporter
activity of wild-type 3′UTR but not mutant 3′UTR of
LRP6 and PIK3R2 and inhibition of miR-126-3p pos-
sessed the opposite results. 3) The effects of miR-126-3p
overexpression on metastasis and angiogenesis could be
phenocopied by suppression of LRP6 and PIK3R2. And
co-transfected of si-LRP6 or restoration of PIK3R2
partly abrogated the effects induced by anti-miR-126-3p
or miR-126-3p mimics, respectively. 4) miR-126-3p level
was inversely correlated with LRP6 and PIK3R2 in HCC
tissues.
LRP6 is a well-known activator of beta-catenin, leading
to pro-proliferation, pro-metastasis and anti-apoptosis in
several cancer types including HCC [21,28,29]. Here, we
demonstrated that overexpression of miR-126-3p led to
down-regulation of LRP6 and its downstream beta-catenin
in vitro and in vivo studies. As LRP6/beta-catenin pathway
is frequently activated in HCC [21,30], the down-regulation
of miR-126-3p might account for this phenomenon. Add-
itionally, PIK3R2, which has been reported to be a target of
miR-126-3p [16,31], was verified to be inversely correlated
with miR-126-3p. We illuminated that overexpression of
miR-126-3p significantly inhibited PIK3R2/P-AKT pathway
in HCC cells and xenografts. PIK3R2/P-AKT pathway,
which is closely related to angiogenesis [22,23], mediates
the effects of miR-126-3p anti-angiogenesis. Recently,
PI3K/P-AKT pathway has been demonstrated to play a
vital role in HCC development [32,33]. PI3K/P-AKT
inhibitors, such as GSK690693, AZD5363 [34,35], are
shown to inhibit the phosphorylation of AKT and then
suppress the progress of cancers. Therefore, the new miR-
126-3p /PIK3R2/P-AKT pathway might serve as a promis-
ing therapeutic target, at least in terms of angiogenesis.
In conclusion, our results show that miR-126-3p is
down-regulated in HCC. Both gain- of function and
loss- of function assays indicate that miR-126-3p sup-
presses metastasis and angiogenesis in HCC cells. We
then investigate the underlying mechanism and find that
miR-126-3p possesses the effects by direct targeting
LRP6 and PIK3R2. So, restoration of miR-126-3p may
represent a promising strategy for anti-HCC therapy.
Conclusion
In this study, we demonstrate that the down-regulation of
miR-126-3p promotes metastasis and angiogenesis by
targeting LRP6 and PIK3R2 in HCC. So restoration of
miR-126-3p might be a candidate therapeutic target for
HCC patients.
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